Spending for Diabetes Drugs is Increasing in the United States

  title={Spending for Diabetes Drugs is Increasing in the United States},
  author={David C. Klonoff},
  journal={Journal of Diabetes Science and Technology},
  pages={543 - 545}
  • D. Klonoff
  • Published 1 July 2008
  • Medicine
  • Journal of Diabetes Science and Technology
As of 2007, the treatment of diabetes has become the leading source of increased spending on prescription drugs. This was reported by Medco Health Solutions Inc. in its 2008 Drug Trend Report, a comprehensive analysis of prescription drug spending and utilization.1 In 2007, diabetes drugs accounted for 7% of prescription drug spending in the United States (U.S.). See Table 1. Table 1 Top Therapeutic Categories Contributing to Drug Spending by Medco in 20071 Diabetes drugs had… 

Tables from this paper

The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes.
It cannot be established that the reduction in costs is solely attributed to the implementation of the HbA1c diagnostic criteria, but further research on healthcare expenditures for diabetic patients diagnosed with and without the use of Hb a1c testing is warranted to establish any possible association.
Generic Drugs : Physician Prescribing Practices for Brand Name and Generic Medications
There were no statistically significant associations between physician belief of cost using generic medications and determinants of physicians’ pattern of prescribing brand-name medications over generic medications, suggesting that Physicians’ prescription patterns are not solely determined by cost of the drug to the patients.
Incretin therapy for type 2 diabetes mellitus
The role of defects in the incretin system in the pathophysiology of type 2 diabetes is reviewed, and recent advances in the use ofincretinbased agents that target the fundamental disease mechanisms of type 1 diabetes are discussed.


Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way
The prevalence of diabetes is projected to rise to substantially greater levels than previously estimated, and diabetes prevalence within the Hispanic community is Projected to be potentially overwhelming.
Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update
In the expectance of proper outcome studies to clarify the effects of these agents in cardiovascular morbidity and mortality, data from recent meta‐analyses suggest that rosiglitazone may increase the risk for some cardiovascular outcomes.
Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
Colesevelam improved glycemic control and reduced LDL cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.
Prescription Drug Use and Expenditures Among Dually Eligible Beneficiaries
The analyses indicate great variation in use and expenditures across States that cannot be explained through differences in use of cost containment strategies, and suggest that Medicare Part D plans may achieve significant savings by providing incentives for greater use of generic drugs.
Total prevalence of diabetes & prediabetes